🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — September 30, 2026

The 10 filings in this S&P 500 Healthcare digest reveal a sector bifurcating between high-growth innovators and defensive operators. Moderna's positive Phase 3 data and new COO appointment signal a strategic pivot toward oncology, while Medtronic's exchange offer to spin off MiniMed highlights a trend of large-cap simplification. Cigna's reaffirmed guidance with a 10-14% long-term EPS growth target contrasts with an expected 83.7-84.7% medical care ratio, indicating margin pressure. Regeneron's new PSU program, with earnout caps and a 20% holdback, suggests a long-term focus on product launches through 2035. Centene's routine director stock awards (totaling 3,715 shares) show no insider selling, a neutral signal. Danaher's delisting of matured notes is a non-event. The sector shows no major guidance cuts; instead, we see capital deployment toward R&D and M&A, with a watchful eye on margin trends and regulatory catalysts.

9 high priority 1 medium 10 total filings
· daily

US Executive Compensation Proxy SEC Filings — September 30, 2026

The 9 DEF 14A filings reveal a mixed governance and compensation landscape across US issuers. Key themes include a notable shift in executive pay structures (Estée Lauder moving to 60% stock options), significant insider buying at Aeluma, and a high-risk SPAC extension vote at Healthcare AI. Kimball Electronics stands out with strong operational metrics (revenue $1.4B, lowest debt in 4 years) and a strategic acquisition, while Nationwide's fund liquidation signals a negative outlook. Period-over-period data shows margin compression at Kimball (4.6% adjusted op margin) and zero PSU payouts at Estée Lauder, indicating performance challenges. Capital allocation trends vary, with buybacks at Kimball and share dilution proposals at Alpha & Omega. The overall sentiment is cautious, with several companies facing governance risks, dilution, or liquidity events, but opportunities exist in undervalued assets, insider conviction, and strategic turnarounds.

9 high priority 9 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 30, 2026

The IPO/follow-on pipeline for the period shows a bifurcated market: two blank-check companies (BHAV, Spark I) are pursuing traditional SPAC capital raises and de-SPAC transactions, while two operating companies (GEN Restaurant Group, Trump Media) are executing highly dilutive and strategically aggressive capital raises. A dominant theme is extreme dilution risk: GEN Restaurant's registration covers 205.5% of shares outstanding, and Trump Media's merger requires a doubling of authorized shares. The SPACs show no revenue and ongoing net losses, with Spark I reporting a $0.5M net loss for both the six-month 2026 and full-year 2025 periods, indicating stable but persistent cash burn. Insider activity is limited but notable: the Trump Revocable Trust's agreement to vote all shares in favor of the TAE merger signals strong insider alignment. Forward-looking catalysts are clustered around shareholder meetings and the effectiveness of registration statements, with the TMTG special meeting and GENK's purchase agreement effective date being key near-term events. Overall, the pipeline is dominated by speculative, event-driven situations with high dilution and binary outcomes, rather than traditional growth IPOs.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — September 30, 2026

The two filings in this digest both involve US-listed companies facing imminent delisting actions from their primary exchanges, signaling a period of heightened regulatory and financial distress in the small/micro-cap biotech and clean-tech sectors. ESS Tech received a NYSE notice on September 24, 2026, for failing to meet the $50M stockholders' equity or market cap standard, while Outlook Therapeutics received a Nasdaq deficiency notice on September 25, 2026, for its sub-$1.00 bid price over 30 consecutive days. Both companies face negative sentiment and high materiality (9/10 and 8/10 respectively), with appeals and cure periods offering only uncertain paths to survival. The concentration of these events within a 24-hour window suggests a broader trend of exchange enforcement tightening on financially distressed issuers, potentially signaling a wave of delistings in the micro-cap space. Investors should monitor the appeal timelines and compliance deadlines closely, as failure to cure will lead to trading suspensions and potential OTCQB/OTCQX downgrades, impacting liquidity and valuation.

2 high priority 2 total filings
· daily

US Executive Officer Management Changes SEC — September 30, 2026

The 25 US SEC filings from 2026-09-30 reveal a pronounced wave of C-suite and board-level transitions across healthcare, financials, industrials, and consumer sectors. Key patterns include a shift toward operational turnarounds (Albertsons, Fortrea, Ultra Clean), strategic CEO successions (Mattel, The Hartford, Cycurion), and a notable uptick in CFO transitions (Levi's, CARs, Xometry, Alphatec). While most changes are routine or planned, several carry material implications: Regeneron's new long-term incentive plan with 10-year equity lockup signals strong governance; Cycurion's legal settlement against an anonymous short-seller highlights an aggressive defense of shareholder value; and Alphatec's CFO departure coincides with reaffirmed 50% revenue growth guidance. No broad-based insider selling or buying patterns emerged, but the concentration of CFO departures in growth-stage companies warrants monitoring. The overall tone is neutral-to-positive, with no major guidance cuts or financial red flags disclosed.

25 high priority 25 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 30, 2026

The September 30, 2026 filings mark a significant escalation in US retail and pharmaceutical distress, with both Petros Pharmaceuticals and Leslie's, Inc. announcing liquidity events that effectively end or restructure their existing equity structures. Petros Pharmaceuticals executed a General Assignment for the Benefit of Creditors (ABC), a state-law alternative to bankruptcy, resulting in an immediate liquidation event, cessation of operations, and triggering of redemption obligations on preferred stock. Leslie's filed for prearranged Chapter 11 with lender support, aiming to eliminate ~90% of its funded debt ($685M) while securing $150M in new capital and closing 76 stores. Both events are characterized by negative sentiment and maximum materiality, reflecting severe operational and balance sheet stress. The period-over-period data, while not providing specific revenue or margin figures, indicates a complete loss of going concern for Petros and a strategic deleveraging for Leslie's. The market implications are stark: equity holders in both companies face near-total value destruction, while creditors and distressed investors see opportunities in the restructuring. The filings highlight a broader theme of retail and specialty pharmaceutical companies struggling with high leverage and shifting consumer dynamics, leading to insolvency proceedings.

2 high priority 2 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 30, 2026

The 25 filings in this digest reveal a pronounced wave of C-suite and board-level transitions across US-listed companies, with a clear sectoral concentration in healthcare, technology, and financials. Key themes include a shift toward operational and financial expertise in boardrooms, a mix of planned successions and involuntary departures, and significant insider activity signaling both confidence and concern. Notable trends include the appointment of CFOs with Big Tech and fintech backgrounds, aggressive equity-based incentive structures tied to long-term performance, and a continued focus on capital returns alongside strategic pivots. The market is digesting these changes against a backdrop of mixed guidance, with some companies reaffirming strong growth while others signal restructuring and cost discipline.

25 high priority 25 total filings
· daily

Biotech Small-Cap Approvals — September 29, 2026

This digest covers 12 FDA approvals from September 22–25, 2026, dominated by generic/biosimilar FALLBACK approvals for established molecules (11 of 12). There were zero NMEs and only one true biosimilar approval (KETOROLAC TROMETHAMINE by Shandong), which is the sole bearish signal for the originator but bullish for the entrant. The highest-conviction event is the bullish NME approval of LIRAFUGRATINIB (LYRFIGTU) by ELEVAR THERAPEUTICS INC, a Priority Review, Orphan-designated drug, signaling a potential high-value commercial launch. No dominant therapeutic area theme emerged from the flurry of low-impact generics, but the generic wave across pain/cardio/diabetes categories underscores ongoing pricing compression in small-molecule primary care markets. Key risk is the IRA exposure of several new generic entrants (e.g., EMPAGLIFLOZIN) and the lack of pipeline innovation from major sponsors in this period.

12 total filings
· daily

NME Blockbuster Approvals — September 29, 2026

During the period of September 29, 2026, the FDA issued a single approval classified as 'Other' (LIRAFUGRATINIB, branded LYRFIGTU, from ELEVAR THERAPEUTICS INC), with no NME, biosimilar, or label expansion approvals recorded. The approval is a bullish signal (strength 8/10, materiality 8/10) for ELEVAR THERAPEUTICS INC, carrying NME, Priority Review, and Orphan Drug designations, indicating significant unmet need and potential for premium pricing and market exclusivity. However, the approval type is flagged as 'FALLBACK,' suggesting a non-standard or contingency pathway that warrants careful monitoring. With only one approval in the period, no dominant therapeutic area theme emerges, and the highest-conviction signal is the LIRAFUGRATINIB approval itself, which could establish ELEVAR as a commercial-stage player. Key risks include the 'FALLBACK' designation, which may imply regulatory or clinical uncertainties, and the lack of disclosed commercial data (peak sales, exclusivity, pricing) limits full investment assessment. Investors should watch for post-approval clinical commitments, launch execution, and payer coverage decisions as near-term catalysts.

1 total filings
· daily

Big Pharma Approvals — September 29, 2026

This digest covers 4 FDA approvals from September 23-25, 2026, all classified as 'Other' (likely label expansions or NMEs with non-standard designations), with 0 NMEs, 0 biosimilars, and 0 standard label expansions. The dominant theme is therapeutic area expansion across immunology (OBINUTUZUMAB/GAZYVA, BARICITINIB/OLUMIANT), oncology (BELZUTIFAN/WELIREG), and metabolic disease (INSULIN EFSITORA ALFA-GOBE/ONSWIK). The highest-conviction signal is ELI LILLY AND CO's NME approval for INSULIN EFSITORA ALFA-GOBE (ONSWIK), a novel insulin therapy with strong bullish signal strength (8/10) and materiality (8/10), positioning LILLY to reinforce its diabetes franchise. Key watch item: the lack of commercial data (peak sales, exclusivity, pricing) for all approvals limits near-term revenue visibility, but the cluster of label expansions from GENENTECH, MERCK, and LILLY signals pipeline execution strength across Big Pharma sponsors.

4 total filings
· daily

Orphan Drug Approvals — September 29, 2026

The September 29, 2026 orphan drug approval stream delivered 4 approvals, all classified as 'Other' (no NMEs, biosimilars, or label expansions per the mix), yet the individual analyses reveal 3 label expansions and 1 NME. The NME, LIRAFUGRATINIB (LYRFIGTU) from ELEVAR THERAPEUTICS INC, is the highest-conviction signal, having received Priority Review and Orphan designation, indicating strong unmet need and a potential premium-priced launch. The three label expansions—OBINUTUZUMAB (GAZYVA) from GENENTECH, LENVATINIB MESYLATE (LENVIMA) from EISAI INC, and BELZUTIFAN (WELIREG) from MERCK SHARP DOHME—are all bullish but lower in strength, suggesting incremental commercial upside. The dominant therapeutic area theme is oncology, with all four drugs targeting oncology indications, signaling continued sector momentum. Key risks include the lack of disclosed commercial data (peak sales, pricing) and potential IRA exposure for small molecules like LENVATINIB and BELZUTIFAN, which could face Medicare price negotiation within 9 years.

4 total filings
· daily

New Drug Approvals (Original) — September 29, 2026

The September 29, 2026 FDA approval stream delivered 13 approvals, comprising 0 NMEs, 1 biosimilar, and 12 other (mostly generic/fallback) approvals, with a notable absence of label expansions. The dominant theme is generic/biosimilar competition across established therapeutic categories, with 12 of 13 approvals being non-NME, signaling a period of market entry rather than innovation. The highest-conviction signals are the two NME approvals: Eli Lilly's INSULIN EFSITORA ALFA-GOBE (ONSWIK) and Elevar Therapeutics' LIRAFUGRATINIB (LYRFIGTU), both flagged as bullish with strong commercial potential. Key risks include the bearish impact of Shandong's first-to-market generic KETOROLAC TROMETHAMINE on the originator, and the absence of NMEs in high-growth areas like oncology or CNS, which may signal a pipeline lull. Watch for commercial launch execution and payer decisions for the two NMEs, as well as the competitive dynamics in the ketorolac market.

13 total filings
· daily

DHS Homeland Security Contracts — September 29, 2026

This digest covers a single $7.0 million firm-fixed-price contract awarded to Lockheed Martin Corp by the U.S. Coast Guard (DHS) for engine nacelles, representing a 100% civilian (DHS) obligation with no defense-related spending. The contract is a low-materiality, sole-source sustainment award that is immaterial to Lockheed Martin’s $60B+ revenue base, generating an estimated $4.67M annualized revenue. The highest-conviction signal is neutral: the award confirms ongoing Coast Guard aircraft sustainment but lacks competitive dynamics, growth options, or technology exposure. The key risk is execution risk on a fixed-price basis for a niche component, though the small size limits downside. No bullish or bearish signals are warranted; the contract is a routine, non-investment-grade event.

1 total filings
· daily

New Federal Contractors — September 29, 2026

This digest covers $269.8M in new federal obligations from a single day (September 29, 2026), with a 97.4% concentration in a single civilian agency award. The dominant signal is a $262.8M sole-source, cost-plus-fixed-fee delivery order from the Department of Transportation’s Maritime Administration to Crowley Government Services, Inc. for Ready Reserve Force vessel recapitalization. This award represents a strategic maritime logistics investment with a 4-year performance window, but its non-competed structure and cost-plus pricing introduce execution and margin uncertainty. The only defense-related contract is a $7M Lockheed Martin firm-fixed-price award from the Coast Guard for engine nacelles—immaterial to Lockheed’s $60B+ revenue base. The highest-conviction signal is the Crowley award’s alignment with national defense logistics priorities, though investors should watch cost performance against the $262.8M ceiling and potential follow-on task orders.

2 total filings
· daily

Significant Contract Modifications ($10M+) — September 29, 2026

The two contracts totaling $269.8M are dominated by a single $262.8M non-competed, cost-plus-fixed-fee delivery order to Crowley Government Services from the Department of Transportation's Maritime Administration for Ready Reserve Force vessel recapitalization, signaling sustained federal investment in strategic maritime logistics. The second contract is a small $7.0M sole-source award to Lockheed Martin from the Coast Guard for engine nacelles, which is immaterial to Lockheed's revenue but confirms ongoing sustainment spending. The highest-conviction signal is the Crowley award's alignment with national defense logistics priorities, though the cost-plus structure and lack of competition introduce execution and margin uncertainty. Key risk: the Crowley contract's 4-year performance period and cost-plus pricing require close monitoring of cost performance and milestone execution against the 2030 deadline.

2 total filings
· daily

Contract Deobligations Alert — September 29, 2026

This digest covers two contracts totaling $269.8M, with a heavy skew toward a single civilian award (97% of value) from the Department of Transportation to Crowley Government Services, Inc. for a $262.8M vessel recapitalization program. The lone defense-related contract is a small $7M sole-source award to Lockheed Martin Corp from the Coast Guard, which is immaterial to that company's top line. The highest-conviction signal is the Crowley award, which, despite being a non-competed cost-plus contract, signals a strategic, multi-year investment in maritime readiness that could provide stable, low-risk revenue for Crowley. The key risk is the cost-plus structure of the Crowley contract, which limits margin upside and introduces execution risk on vessel delivery milestones through 2030.

2 total filings
· daily

Contract Option Exercises — September 29, 2026

The two contract awards on September 25-27, 2026 total $269.8M, split between one civilian (DOT/Maritime Administration) and one defense-related (DHS/Coast Guard) action. The dominant theme is maritime readiness: a $262.8M cost-plus-fixed-fee delivery order to Crowley Government Services for vessel recapitalization of the Ready Reserve Force, and a $7M sole-source firm-fixed-price contract to Lockheed Martin for Coast Guard engine nacelles. The highest-conviction signal is the Crowley award, which signals sustained federal investment in strategic maritime logistics despite execution risk from the cost-plus structure. Key watch item: Crowley's ability to meet vessel delivery milestones by 2030 under a non-competed arrangement.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — September 29, 2026

A single mega contract ($262.8M) from the Department of Transportation’s Maritime Administration to Crowley Government Services, Inc. for vessel recapitalization under the Ready Reserve Force program represents a civilian maritime logistics investment with national defense implications. The non-competed, cost-plus-fixed-fee structure signals a strategic sole-source relationship but introduces execution and margin uncertainty. No defense-related awards were recorded in this period, highlighting a civilian-led procurement focus. The highest-conviction signal is the sustained federal commitment to maritime readiness, though investors should monitor cost performance and potential follow-on task orders as key catalysts.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 29, 2026

This digest covers two contracts totaling $269.8M, with a stark 97.5% concentration in a single civilian award to Crowley Government Services. The dominant theme is strategic maritime readiness investment by the Department of Transportation’s Maritime Administration, which awarded a $262.8M sole-source, cost-plus contract for vessel recapitalization. The highest-conviction signal is the neutral-to-bullish implication for Crowley’s maritime logistics franchise, though the cost-plus structure and lack of competition cap margin upside. A minor $7M Lockheed Martin award to the Coast Guard is immaterial. The key risk is execution and cost overrun on the Crowley contract, given the complex vessel survey and modification scope under a cost-plus arrangement.

2 total filings
· daily

General Federal Contracts — September 29, 2026

The September 29, 2026 federal contracts digest totals $269.8M in obligations, with a 50/50 defense/civilian split by contract count but a heavily civilian-weighted dollar value, driven by a single $262.8M non-competed cost-plus-fixed-fee delivery order from the Department of Transportation's Maritime Administration to Crowley Government Services for Ready Reserve Force vessel recapitalization. The only defense-related award is a $7.0M sole-source firm-fixed-price contract to Lockheed Martin from the U.S. Coast Guard for engine nacelles, which is immaterial to Lockheed's revenue but signals continued sustainment spending. The highest-conviction signal is the Crowley award's strategic maritime logistics investment, though its cost-plus structure and lack of competition introduce execution and margin uncertainty. Key watch items include Crowley's cost performance against the $262.8M ceiling and potential follow-on task orders, as well as any budget-driven disruptions to maritime readiness programs under a continuing resolution.

2 total filings